• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Amyotrophic lateral sclerosis Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Amyotrophic lateral sclerosis.
  • The report assesses Amyotrophic lateral sclerosis pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Amyotrophic lateral sclerosis pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Amyotrophic lateral sclerosis ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Sanofi-Synthelabo, Sanofi-aventis, Fidia Farmaceutici; Roche Palo Alto LLC, Toyama Chemical, Mitsubishi Pharma Corporation, Pharmacyclics, Cephalon, Regeneron Pharmaceuticals, Santen Pharmaceutical, Ono Pharmaceutical, Purdue Pharma, Vasogen, SYGNIS Bioscience GmbH, Phytopharm, Rinat Neuroscience, ViaCell, Faust Pharmaceuticals, Eisai Co Ltd, Isis Pharmaceuticals, NeuroNova AB, Sangamo BioSciences, Psyadon Pharmaceuticals, Sirtris Pharmaceuticals, CepTor Corporation, Metabolic Pharmaceuticals, Neuren Pharmaceuticals, Celgene Corporation, Cambria Biosciences LLC, Metabolon, GEMACBIO, Saneron CCEL Therapeutics, Reata Pharmaceuticals, Trophos, Avicena Group, Addex Pharmaceuticals, Neurosciences Victoria, Neurotune, ReceptoPharm, Neuralstem, KineMed, Anavex Life Sciences, Genzyme Corporation

Key Drugs:

Eliprodil, Xaliproden, T 588, Oxothiazolidine carboxylate, Edaravone, Riluzole, Motexafin gadolinium, Neurturin, Mecasermin, Dapiclermin, Cutamesine, Talampanel, ARR 17477, ZVAD fmk, WHIP 131, Arundic acid, GPI 5693, PC 01, EN 101

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel